Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Monday. $113.33 million flowed into the stock on the tick-up and $231.62 million flowed out of the stock on the tick-down, for a money net flow of $118.29 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 6th highest net out-flow for the day. Johnson & Johnson traded up $0.47 for the day and closed at $139.96
Several equities research analysts have issued reports on the stock. Wells Fargo & Co reiterated an “outperform” rating and set a $160.00 price objective on shares of Johnson & Johnson in a research note on Friday. ValuEngine downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Tuesday, May 22nd. Jefferies Financial Group set a $145.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Sunday, July 15th. Credit Suisse Group set a $151.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a research note on Tuesday, June 12th. Finally, Sanford C. Bernstein assumed coverage on shares of Johnson & Johnson in a research note on Wednesday, June 27th. They set a “market perform” rating and a $129.00 price objective for the company. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $142.87.
The company has a market cap of $373.89 billion, a price-to-earnings ratio of 19.17, a price-to-earnings-growth ratio of 2.13 and a beta of 0.69. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, July 17th. The company reported $2.10 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.04. The business had revenue of $20.83 billion during the quarter, compared to the consensus estimate of $20.39 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.83 earnings per share. analysts forecast that Johnson & Johnson will post 8.14 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which was paid on Tuesday, September 11th. Stockholders of record on Tuesday, August 28th were paid a $0.90 dividend. The ex-dividend date was Monday, August 27th. This represents a $3.60 annualized dividend and a dividend yield of 2.57%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.
In related news, CAO Ronald A. Kapusta sold 7,899 shares of the company’s stock in a transaction on Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the sale, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael E. Sneed sold 29,000 shares of the company’s stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the sale, the chief operating officer now directly owns 59,124 shares in the company, valued at $7,969,915.20. The disclosure for this sale can be found here. 0.22% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. raised its holdings in shares of Johnson & Johnson by 1.7% during the second quarter. BlackRock Inc. now owns 178,310,265 shares of the company’s stock worth $21,636,166,000 after purchasing an additional 2,921,241 shares during the period. Phocas Financial Corp. raised its holdings in shares of Johnson & Johnson by 999,927.7% during the second quarter. Phocas Financial Corp. now owns 129,463,583 shares of the company’s stock worth $1,571,000 after purchasing an additional 129,450,637 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Johnson & Johnson by 0.6% during the second quarter. Bank of New York Mellon Corp now owns 33,456,996 shares of the company’s stock worth $4,059,673,000 after purchasing an additional 185,136 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in shares of Johnson & Johnson by 1.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 30,303,272 shares of the company’s stock worth $3,676,999,000 after purchasing an additional 541,338 shares during the period. Finally, Glenmede Trust Co. NA raised its holdings in shares of Johnson & Johnson by 149.8% during the second quarter. Glenmede Trust Co. NA now owns 22,174,682 shares of the company’s stock worth $2,690,676,000 after purchasing an additional 13,295,992 shares during the period. 66.80% of the stock is currently owned by hedge funds and other institutional investors.
About Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: What do investors mean by earnings per share?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.